ADGM

Adagio Medical Holdings, Inc. (ADGM) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Adagio Medical Holdings, Inc. is a medical technology company developing ablation technologies for cardiac arrhythmias, specifically ventricular tachycardia (VT), using its proprietary Ultra-Low Temperature Ablation (ULTA) platform. The company is currently focused on the regulatory approval of its vCLAS Ventricular Ablation System, for which a Premarket Approval (PMA) application was submitted to the FDA in May 2026 following the completion of the FULCRUM-VT pivotal trial.

Key Financial Metrics

Note: The company reported zero revenue for the periods presented due to a strategic pause in commercial activities in Europe to prioritize U.S. regulatory approval.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the three months ended June 30, 2026, increased to $6.7 million from $3.9 million in the same period in 2025. For the six months, the loss increased to $13.7 million from $11.7 million.
• Non-Cash Fair Value Adjustments: A significant driver of the increased loss was a $2.2 million loss on the fair value adjustment of convertible notes for the six months ended June 30, 2026, compared to a $1.6 million gain in the prior year period. This was driven by a decline in the company's stock price and increased volatility inputs.
• Operating Expenses: Total operating expenses decreased by 17% for the six-month period ($10.1 million vs. $12.2 million), primarily due to reduced clinical trial and professional service costs, partially offset by higher operational costs.
• Liquidity: Cash and cash equivalents decreased by approximately $9.4 million during the six-month period, dropping from $17.1 million at year-end 2025 to $7.7 million.

Outlook, Risks, and Management Commentary

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of June 30, 2026, cash resources are estimated to fund operations only into the fourth quarter of 2026. The company plans to mitigate this through cost-cutting, strategic financing, and pursuing regulatory approvals.
• Regulatory Milestones: The company submitted a PMA application for the vCLAS system in May 2026. It also received FDA IDE approval in April 2026 to expand trials for its next-generation vCLAS Ultra system.
• Nasdaq Compliance: On June 12, 2026, the company received notice from Nasdaq regarding non-compliance with the Minimum Bid Price Requirement (stock price below $1.00 for 30 consecutive days). The company has until December 9, 2026, to regain compliance or risk delisting.
• Warrant Expirations: Tranche A Warrants from the 2025 PIPE financing expired unexercised in May 2026. Remaining Tranche B and C warrants are tied to future FDA approvals.

Investor Verification Checklist

• Cash Runway: Verify the timeline for securing additional financing, as current cash ($7.7M) is projected to last only until Q4 2026.
• Convertible Note Liability: Monitor the fair value of the $24.8M convertible notes, as fluctuations in stock price and volatility significantly impact reported net loss.
• Nasdaq Listing Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement by December 9, 2026, to avoid delisting.
• Regulatory Decision: Await the FDA's decision on the PMA application submitted in May 2026, which is critical for future revenue generation.
• Warrant Exercise: Assess the likelihood of the remaining Tranche B and C warrants being exercised, contingent on future FDA approvals.